Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28741984 | 0.88 | OPRM1 (0.53) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL24770748 | 0.87 | OPRM1 (0.57) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL22966099 | 0.85 | OPRM1 (0.53) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL9884888 | 0.84 | OPRM1 (0.52) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL4005143 | 0.82 | L3MBTL1 (0.41) | ACHE | |
| Hydrochloric Acid SCHEMBL8479224 | 0.82 | OPRM1 (0.51) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL16054269 | 0.80 | OPRM1 (0.59) | CHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL1715453 | 0.80 | HRH3 (0.50) | CHRM2CHRM3OPRM1CHRM4 | |
| SCHEMBL12347237 | 0.80 | OPRM1 (0.51) | CHRM2CHRM3OPRM1ACHESIGMAR1 | |
| SCHEMBL5534758 | 0.80 | OPRM1 (0.60) | CHRM2CHRM3OPRM1ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080565-B2 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-22 | — | — | US | disclosed |
| US-7368463-B2 | Substituted 4-amino-1-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1644356-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | Theravance, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2005007645-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | CHRM2 4/4885CHRM3 2/4885OPRM1 86/4885 |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | CHRM5, CHRM3, GPR4 | CHRM2 13/4885CHRM3 2/4885OPRM1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.